

CURRICULUM VITAE

■ Andrew Evans

Address: 6 Bayswater Rd., Wallasey, Merseyside. CH45 8JZ
Telephone: 0151 231 2145
E-mail: A.R.Evans@ljmu.ac.uk
Date of birth: 22/03/1959



■ Education

Date	Establishment	Achievements	Projects
1999-2003	School of BioMolecular Sciences, Liverpool John Moores University	PhD	PhD project: Gene therapy for cystic fibrosis; An investigation into the potential toxicity and transfection efficiency of non-viral transfection reagents for delivery to the airways. Funding: BBSRC industrial case studentship with GlaxoSmithKline
1995 - 1999	Liverpool University <i>School of Biological Sciences prize for Molecular Biology Honours 1999</i>	Bsc (Hons) 2:1 Molecular biology	Final year project: Analysis of cloned cDNAs from a subtracted library corresponding to mRNAs of potential tumour suppressor genes.

■ Employment

Date	Employer	Position	Description
2005-to date	School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University	Senior Lecturer in Pharmacology	Teaching undergraduate and postgraduate students. Module and subject area leadership. Research.
2003-2005	School of Pharmacy & Chemistry, Liverpool John Moores University	Post-doctorial research scientist	Project title: Facilitative Glucose Transporter GLUT-1: A Target for Novel Anti-cancer Agents. Research and supervision of practical work of PhD students and undergraduates. Funding: Association of International Cancer Research (AICR)
1996-2003	In Education		
May 1995	Pharmaserve Ltd., Manchester	Clinical research assistant	Assisting in the collection, checking and processing of clinical data relating to trials of novel drugs.

■ Research

Research Supervisory Responsibilities

PhD Students:

- Marine Bastien. 'Mechanisms of pathological adipogenesis'. (Funded by the School of Pharmacy and Biomolecular Sciences). (2nd supervisor)
- Afaf Mohammed Omar Al-Groshi. 'Bioassay guided isolation of potential anticancer compounds from selected Libyan medicinal plants'. (Funded by the Botany Department, Faculty of Science, Tripoli University). (2nd supervisor)
- Sikander Sharma. 'The role of HMGB1 in relation to myofibroblasts and cancer cells exposed to various microenvironmental stress conditions'. (Funded by the School of Pharmacy and Biomolecular Sciences). (Director of Studies)
- Victoria Bates. 'Influence of Glut-1 on response to bioreductive drugs in bladder cancer'. (Funded by European Union Framework VI). (Director of Studies)
- Katarzyna Bloch. 'Gene expression profiling in rat renal cells exposed *in vitro* to genotoxic and non-genotoxic renal carcinogens'. (Funded by an EU 6th Framework-Carcinogenomics grant) (2nd supervisor)
- Noreen Yaqoob. 'Studies on trichloroethylene-induced formic aciduria'. (funded partly by the Halogenated Solvents Industries of America and Syngenta, UK). (2nd supervisor)

MPhil Students:

- Kathryn Mason. 'An ICH compliant stability study of monoclonal antibody drug bevacizumab (Avastin®)'. (Funded by Quality Control North West (QCNW) and the NHS as part of a larger National study (VEGF in Age-related choroidal Neovascularisation study (IVAN))). (Director of Studies)
- Heather Kean. 'Compatibility studies of frequently used drug combinations used for pain and symptom management in end of life care'. (Funded by Quality Control North West (QCNW) and the Marie Curie Palliative Care Institute, Liverpool). (Director of Studies)

MSc Clinical Research Students:

- Ruth Boyd. 'A comparison of symptom-related adverse event detection and grading, using a patient self-reported questionnaire (Modified Chemotherapy – Symptom Assessment Scale) versus 'routine' symptom assessment in cancer chemotherapy clinical trials: A pilot study'. (self-funded). (Academic supervisor)

- Susan Palmer. 'Does research awareness impact on accrual? A feasibility study' (self-funded). (Academic supervisor)

■ Collaborative Links

- Dr Phil Weir - Research and Scientific Services, Quality Control North West (QCNW), Stepping Hill Hospital, Manchester UK.
- Dr Roger Phillips - Tom Connors Cancer Research Unit, University of Bradford, UK. *in vivo* tumour biology of hypoxia and glucose transport and translational research in bladder cancer
- Dr Edward Estlin - Royal Manchester Children's Hospital, Department of Oncology, Manchester, UK. Translational research in children's cancer, hypoxia, angiogenesis and glucose transport and influence on chemosensitivity and survival
- Dr Rachael Airley, Department of Pharmacy, Huddersfield University, UK. The role of carbohydrate response element-binding protein (ChREBP) in cancer
- Jonai Pujol Gimenez - Department of Nutrition, Food Science and Physiology, University of Navarra, Pamplona, Spain. Role of Glut-12 glucose transporter in cancer

■ Professional Association Membership

- British Association of Cancer Research (BACR)

■ Publications

Published Papers

Sharma, S., Hemers, E. & Evans, A.R. Mesenchymal-epithelial signaling in the tumour microenvironment: The role of High-Mobility Group Box 1 . (2016). *Cell Tissue Res.*, published initially online on 16th March 2016.

Bloch, K.M., Yaqoob, N., Sharma, S. Evans, A., Aschauer, L., Radford, R., Jennings, P., Ryan, M.P., van Delft, J.H.M. & Lock, E.A. Transcriptomic alterations induced by Monuron in rat and human renal proximal tubule cells *in vitro* and comparison to rat renal-cortex *in vivo*. (2015). *Toxicol. Res.*, **4**, 423-431.

Bloch, K.M., Evans, A.R. & Lock, E.A. Aristolochic acids - Induced transcriptomic responses in rat renal proximal tubule cells *in vitro*. (2015). *Genomics Data*, **5**, 254-256.

Pujol-Gimenez, J., Pérez de Heredia, F., Idoate, M.A., Airley, R., Lostao, M.P. & Evans, A. R. Could GLUT12 be a potential therapeutic target in cancer? A preliminary report. (2015). *J. Cancer*, **6**, 139-143.

Yaqoob, N., Evans, A.R., Foster, J.R. & Lock, EA. Trichloroethylene and trichloroethanol-induced formic aciduria and renal injury in male F-344 rats following 12 weeks exposure. (2014). *Toxicol.*, **323**, 40-77.

Airley, R.E., McHugh, P., Evans, A.R., Harris, B., Winchester, L., Buffa, F.M., Al-Tameemi, W., Leek, R. & Harris, A.L. Role of carbohydrate response element-binding protein (ChREBP) in generating an aerobic metabolic phenotype and in breast cancer progression. (2014). *Brit. J. Cancer*, **110**, 715-723.

Tawfeek, H.M., Evans, A.R., Iftikhar, A., Mohammed, A.R., Shabir, A., Somavarapu, S., Hutcheon G.A. & Saleem, I.Y. Dry powder inhalation of macromolecules using novel PEG-co-polyester microparticle carriers. *Int. J. Pharm.*, (2013), **441**, 611-619.

Yaqoob, N., Evans, A.R. & Lock, E.A. Trichloroethylene-induced formic aciduria: effect of dose, sex and strain of rat. (2012). *Toxicol.*, **304**, 49-56.

Airley, R. & Evans, A.R. How the science of personalized medicines will change the clinical management of patients in the pharmacy. (2012). *Future Med. Chem.*, **4**, (16), 2023-2027.

Bloch, K.M., Yaqoob, N., Evans, A.R., Radford, R., Jennings, P., Boei, J.J.W.A., McMorro, T., Slattery, C., Ryan, M.P., Gmuender, H., van Delft, J.H.M & Lock, E.A. Detection of genotoxic and non-genotoxic renal carcinogens *in vitro* in NRK-52E cells using a transcriptomics approach. (2012). *Toxicol. Res.*, **1** (3), 211-219.

Airley, R., Evans, A.R., Mobasheri, A. & Hewitt, S.M. Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays. (2010). *Ann. Anat.*, **192**, 133-138.

Evans, A.R, Bates, V., Troy, H., Hewitt, S., Holbeck, S., Chung, Y-L., Phillips, R., Stubbs, M., Griffiths, J. & Airley, R. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies (2008). *Cancer Chemother. Pharmacol.*, **61**, 377-393.

Airley, R., Phillips, R.M., Evans, A.R., Double, J., Burger, A.M., Feibig, H.H., West, C.M.L. & Stratford, I.J. Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: Results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. (2005). *Int. J. Oncol.*, **26**, 1477-1484.

Textbook

Evans, A.R. Molecular Cell Biology. Chapter in 'Therapeutics and Human Physiology: How drugs work' (Integrated Foundations Of Pharmacy). (2013). Editors: Gaskell, E. & Rostron, C. *Oxford University Press, Oxford*.

Published Abstracts

Shepherd, S.L., Chapman, L., Allison, G., Day, S., McHugh, P., Evans, A. & Airley, R. The development of drug sensitivity biomarkers for personalised cancer chemotherapy. (2014). *American Society of Clinical Oncology Annual Meeting, Chicago, USA*

Airley, R., Evans, A.R., Harris, B., Winchester, L., Leek, R. & Harris, A. Carbohydrate response element binding protein (ChREBP) - a new metabolic biomarker in breast cancer? (2012). *Eur. J. Cancer*, **48**, suppl. 5, S80.

Sharma S, Hemers E, Evans A. Investigation into the role of HMGB1 in relation to myofibroblasts and cancer cells exposed to various microenvironmental stress conditions. (2012). *National Cancer Research Institute (NCRI), Liverpool*. NCRI Poster Abstracts (B173)

Bloch, K.M., Evans, A.R., van Delft, J. & Lock, E.A. Detection of renal genotoxic carcinogens using NRK52E cells - a normal rat renal proximal tubule cell line with an external metabolising system. (2012). *British Toxicology Society annual meeting poster abstract*.

Bloch, K.M., Evans, A.R., van Delft, J. & Lock, E.A. Genome-wide expression profiling in rat kidney and a rat kidney cell line NRK-52E following short-term exposure to Monuron. (2012). *British Toxicology Society annual meeting poster abstract*.

Bloch, K.M., Evans, A.R., van Delft, J. & Lock, E.A. The effect of four non-genotoxic carcinogens and four non-carcinogens on NRK-52E cells using a transcriptomics approach. (2011). *Toxicol*, **290**, 110-110.

Sharma S, Hemers E, Evans A. Investigation into the role of HMGB1 in relation to myofibroblasts and cancer cells exposed to various conditions. (2011). *LJMU Institute for Health Research Conference (IHR), Liverpool*. IHR poster abstracts (7).

Lilley, L., Downing, J. & Evans A.R. Treatment with components of grapefruit juice can reverse drug resistance in bladder cancer cells resistant to chemotherapeutic agent epirubicin *in vitro*. (2011). *LJMU Institute for Health Research Conference (IHR)*. Liverpool. IHR poster and talk abstract.

Sharma, S., Hemers, E. & Evans, A.R. Investigation into the role of HMGB1 in relation to myofibroblasts and cancer cells exposed to various conditions. (2011). *National Cancer Research Institute (NCRI)*. Liverpool. NCRI Poster Abstracts (p. 283).

Tawfeek, H.M., Khidr, S.H., Samy, E.M., Ahmed, S.M., Evans, A.R., Gaskell, E.E. & Hutcheon, G.A. Encapsulation, release, bioactivity and cytotoxicity of lysozyme loaded poly(glycerol adipate-co-omega-pentadecalactone) microparticles. (2010). *J. Pharm. Pharmacol.*, (vol. 62, pp. 1431-1432).

Mc Allister, L., Evans, A.R., Hutcheon, G. & Gaskell, E. Encapsulation of epirubicin for the treatment of cancer. (2009). *J. Pharm. Pharmacol.*, Sept. suppl., A77.

Bloch, K., Evans, A.R., & Lock, E.A. Developing an *in vitro* method for assessing the carcinogenic potential of compounds to the kidney. (2009). *Toxicol.*, **262**, 9-9.

Hodgson, G., Evans, A.R. & Airley, R. Deregulated glucose transport as a target for anticancer drug development: use of a Glut-1 over-expressing colon carcinoma cell line to screen tyrosine kinase inhibitors for Glut-1-dependant toxicity. (2005). *J. Pharm. Pharmacol.*, Sept. suppl., S-76.

Lonergan, S., Haddad, N., Evans, A.R. & Airley, R. Ascorbic acid toxicity in tumours: role of facilitative glucose transporter Glut-1 and hypoxia. (2005). *J. Pharm. Pharmacol.*, Sept. suppl., S-77.

Olidimeji, B., Ierston, S., Evans, A.R., Estlin, E. & Airley, R. Bone marrow hypoxia as a target in acute lymphoblastic leukaemia: toxicity assays using the bioreductive cytotoxic agent Tirapazamine. (2005). *J. Pharm. Pharmacol.*, Sept. suppl., S-77.

Evans, A.R., Brittain-Dissont, S., Williams, K.J., Stratford, I.J., & Airley, R.E. The facilitative glucose transporter GLUT-1 as a target for novel anti-cancer agents. (2004) *Eur. J. Cancer*, **2** (Suppl.)

Brittain-Dissont, S.J., Williams, K.J., Sheppard, F., Evans, A.R., Carruthers, A., Stratford, I. & Airley, R. Role of glucose transporter Glut-1 in tumour growth and response to therapy. (2004). *Br. J. Cancer*, **91** (Suppl. 1)

Hermitage, N., Evans, A.R., Houghton, P., Stratford, I., Estlin, E. & Airley, R. Hypoxia-regulated gene expression in rhabdomyosarcoma cell lines. (2004). *Br. J. Cancer*, **91** (Suppl. 1)

Santos, K., Evans, A.R., Kelsey, A., Wynn, R., Estlin, E. & Airley, R. Is hypoxia a therapeutic target in haematological malignancies? Glut-1 and LDH expression in acute lymphoblastic leukaemia. (2004). *Br. J. Cancer*, **90** (Suppl 1)

Lunt, A., Evans, A.R., Houghton, P., Stratford, I., Estlin, E. & Airley, R. The role of MYCN amplification and hypoxia in the expression of facilitative glucose transporters in neuroblastoma cell lines. (2004). *Br. J. Cancer*, **91** (Suppl. 1)

Evans, A.R., Hewitt, S., Stratford, I. & Airley, R. Glut-1 as a novel target for anticancer therapy: a COMPARE analysis using the NCI panel of 60 cell lines. (2003). *Br. J. Cancer*, **88** (Suppl. 1)

Evans, A.R., Alexander, D., Burke, P. & Reed, C. J. Toxicity and transfection efficiency: comparison between four commercially available non-viral transfection reagents in a human bronchial epithelial cell line. (2001). *British Pharmaceutical Conference Abstract Book*: **106**.